SCHEMBL4112288

SCHEMBL4112288

CC(C)Oc1cccc(NC(=O)Nc2ccc(F)c(F)c2)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.63
CA2 P00918 1/20 0.63
MEN1 O00255 4/20 0.56
KMT2A Q03164 4/20 0.56
ALDH1A1 P00352 1/20 0.56
BRAF P15056 1/20 0.55
TP53 P04637 1/20 0.54
TSHR P16473 1/20 0.54
EPHX2 P34913 1/20 0.52
MAPT P10636 4/20 0.51
GAA P10253 1/20 0.51
RAB9A P51151 4/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
NPC1 O15118 3/20 0.50
CCR2 P41597 1/20 0.49
PLAU P00749 2/20 0.49
LMNA P02545 2/20 0.49
HTT P42858 2/20 0.49
F2 P00734 1/20 0.49
PLG P00747 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4111961 0.89 CA2 (0.60) CNR1CA2MEN1KMT2ABRAF
SCHEMBL4110800 0.89 CNR1 (0.60) CNR1CA2MEN1KMT2ATP53
SCHEMBL4117340 0.89 MAPT (0.56) CNR1CA2MEN1KMT2AALDH1A1
SCHEMBL4116643 0.89 CA2 (0.70) CNR1CA2MEN1KMT2AALDH1A1
SCHEMBL4110991 0.86 MEN1 (0.63) CNR1CA2MEN1KMT2ABRAF
SCHEMBL4105980 0.84 CNR1 (0.85) CNR1CA2MEN1KMT2ATP53
SCHEMBL4105824 0.84 CA2 (0.61) CNR1CA2MEN1KMT2AALDH1A1
SCHEMBL4104406 0.84 CA2 (0.71) CNR1CA2MEN1KMT2AALDH1A1
SCHEMBL4112018 0.83 CA2 (0.70) CNR1CA2MEN1KMT2AALDH1A1
SCHEMBL4113053 0.83 CNR1 (0.70) CNR1CA2MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists CNR1, CNR2, OPRL1 CNR1 1/4885CA2 4345/4885MEN1 3273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.